{
    "ticker": "H",
    "name": "Horizon Therapeutics plc",
    "description": "Horizon Therapeutics plc is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines that address critical needs for patients with rare and rheumatic diseases. Founded in 2008 and headquartered in Dublin, Ireland, Horizon has established a strong presence in the pharmaceutical industry, particularly in the areas of rare autoimmune diseases and other high unmet medical needs. The company\u2019s product portfolio includes several key therapies such as Tepezza (teprotumumab), which is used for the treatment of thyroid eye disease, and Krystexxa (pegloticase), for chronic gout. Horizon is dedicated to advancing science and addressing the needs of patients through robust clinical research programs and collaborations. With a commitment to patient-centric solutions, Horizon aims to provide meaningful innovations and support the communities it serves. The company\u2019s mission is to improve the lives of patients by delivering high-quality treatments and advancing healthcare through scientific discovery and compassionate care.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Dublin, Ireland",
    "founded": "2008",
    "website": "https://www.horizontherapeutics.com",
    "ceo": "Tim Walbert",
    "social_media": {
        "twitter": "https://twitter.com/HorizonThera",
        "linkedin": "https://www.linkedin.com/company/horizontherapeutics/"
    },
    "investor_relations": "https://investors.horizontherapeutics.com",
    "key_executives": [
        {
            "name": "Tim Walbert",
            "position": "CEO"
        },
        {
            "name": "Jeffrey K. McMurray",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Rare Disease Treatments",
            "products": [
                "Tepezza",
                "Krystexxa"
            ]
        },
        {
            "category": "Rheumatic Disease Treatments",
            "products": [
                "Ravicti",
                "Actimmune"
            ]
        }
    ],
    "seo": {
        "meta_title": "Horizon Therapeutics | Innovative Medicines for Rare and Rheumatic Diseases",
        "meta_description": "Horizon Therapeutics plc focuses on developing innovative therapies for patients with rare autoimmune and rheumatic diseases. Explore our commitment to patient care and scientific advancement.",
        "keywords": [
            "Horizon Therapeutics",
            "Biopharmaceuticals",
            "Rare Diseases",
            "Rheumatic Diseases",
            "Tepezza",
            "Krystexxa"
        ]
    },
    "faq": [
        {
            "question": "What does Horizon Therapeutics specialize in?",
            "answer": "Horizon Therapeutics specializes in the development of innovative medicines for rare and rheumatic diseases."
        },
        {
            "question": "Who is the CEO of Horizon Therapeutics?",
            "answer": "The CEO of Horizon Therapeutics is Tim Walbert."
        },
        {
            "question": "Where is Horizon Therapeutics headquartered?",
            "answer": "Horizon Therapeutics is headquartered in Dublin, Ireland."
        },
        {
            "question": "What are some of Horizon's key products?",
            "answer": "Key products include Tepezza and Krystexxa."
        },
        {
            "question": "When was Horizon Therapeutics founded?",
            "answer": "Horizon Therapeutics was founded in 2008."
        }
    ],
    "competitors": [
        "AMGN",
        "BIIB",
        "GILD",
        "REGN"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "ABBV"
    ]
}